NCT06857175
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 37 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Enrollment target: estimated 508 to confirmed 515
- Secondary endpoints: details revised at 1 of 5 entries
- Site details revised
- Minor Study title revisedv5
- Minor Enrollment target: 674 to 508v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria shortened, about 4 words
- Start date changed from estimate of Mar 2025 to Mar 25, 2025
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Participants receive BL-B01D1 in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Participants receive Docetaxel or Paclitaxel in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Drugs: BL-B01D1, Docetaxel or Paclitaxel
Sites
1 site in 1 country
- Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China